The Patent Finder

CSPC Megalith Biopharmaceutical Co., Ltd.

11 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

0
Ending by 2030
Jun 2035
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 23, 2027
    The maintenance fee for Homogenous antibody drug conjugates via enzymatic methods (US 10,357,472) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
  • 1 fee due May 12, 2027
    The maintenance fee for Homogenous antibody drug conjugates via enzymatic methods (US 10,471,037) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
  • 1 fee due Nov 5, 2027
    The maintenance fee for Homogenous antibody drug conjugates via enzymatic methods (US 10,639,291) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 3 of the patents on this record were granted since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,357,472Homogenous antibody drug conjugates via enzymatic methods
In force
 · USPTO record
In forceUSPTO record
US 10,471,037Homogenous antibody drug conjugates via enzymatic methods
In force
 · USPTO record
In forceUSPTO record
US 10,639,291Homogenous antibody drug conjugates via enzymatic methods
In force
 · USPTO record
In forceUSPTO record
US 11,285,128Homogenous antibody drug conjugates via enzymatic methods
In force
 · USPTO record
In forceUSPTO record
US 11,407,828Anti-CLauDiN 18 antibodies and methods of use thereof
In force
 · USPTO record
In forceUSPTO record
US 12,679,890Anti-Claudin 18 Antibodies and Methods of Use Thereof
In force
 · Low confidence
In forceLow confidence
US 12,458,818Anti-trophoblast cell surface antigen 2 (TROP2) antibodies and antibody drug conjugates comprising same
In force
 · USPTO record
In forceUSPTO record
US 12,559,534Modified IL-2 Proteins, Peg Conjugates, and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 12,723,100NECTIN-4 Antibodies and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 12,741,032ANTI-CLDN182 Antibody, Drug Conjugate, and Preparation Method Therefor and Use Thereof
In force
 · High confidence
In forceHigh confidence
10 of 11 patents shown.
Pro members see all 11.
Pro members: see all 11 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 1 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited